HC Wainwright & Co. Maintains Buy on Acrivon Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Acrivon Therapeutics (NASDAQ:ACRV) and raises the price target from $20 to $22.
May 14, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics' Buy rating is maintained by HC Wainwright & Co., with an increased price target from $20 to $22, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong conviction in the company's future performance and growth prospects. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100